PerkinElmer and Axxam to Deliver Advanced Screening Solutions for Drug Discovery.

* PerkinElmer Obtains Exclusive Rights to Commercialize Axxam's Photina([R]) Technology

* Provides Customers with a Comprehensive Solution for Luminescence Screening

WALTHAM, Mass. -- PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics,

today announced that it signed a worldwide licensing agreement with Axxam SpA, a Milan, Italy-based company focused on early-stage discovery research and services for the life science industry, to become the exclusive provider of Axxam's Photina([R]) photoprotein technology to the drug discovery market. The Photina([R]) technology is a luminescent cell-based assay platform optimized for screening important drug discovery targets, including G-protein coupled receptors (GPCRs) and ion channels. The terms of the agreement also provide for a formal research and development program between PerkinElmer and Axxam to develop additional Photina([R]) GPCR and ion channel cell lines for use in high throughput screening and compound profiling. Axxam retains the rights to use the technology for its discovery services to third parties.

"This agreement strengthens our position as a leading supplier of GPCR screening solutions and continues our efforts to build the most comprehensive offering in cellular screening and drug discovery reagent technologies," said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. "The addition of the Photina([R]) platform enables PerkinElmer to support our biopharmaceutical customers with a comprehensive solution for luminescence screening technology as they transition from traditional fluorescence assay platforms to more efficient, cost effective luminescence platforms."

Today's announcement builds upon PerkinElmer's recent acquisition of Euroscreen Products and its innovative AequoScreen([R]) aequorin-based cellular assay platform. The combination of the AequoScreen and Photina([R]) technologies allows PerkinElmer to provide its customers with a total solution for flash luminescence instrumentation and reagents. Both the AequoScreen and Photina([R]) platforms are based on a proven luminescence technology that generates higher quality data, while reducing the number of false positives in GPCR and ion channel screening applications. PerkinElmer estimates that more than half of all high throughput screening laboratories will move from traditional kinetic fluorescence assays to flash luminescence technologies within two years.

The Photina([R]) platform complements PerkinElmer's existing assay development platforms, including VICTOR[TM] Light, EnVision([R]) Cell Station, MicroBeta([R]) JET and LumiLux([R]) cellular screening platform, which have broad potential for identifying cellular targets in a wide range of disease areas.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.